Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01506609
Registration number
NCT01506609
Ethics application status
Date submitted
6/01/2012
Date registered
10/01/2012
Titles & IDs
Public title
Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer
Query!
Scientific title
A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer
Query!
Secondary ID [1]
0
0
2011-002913-12
Query!
Secondary ID [2]
0
0
M12-895
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Metastatic Breast Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional(has expanded access)
Query!
Description of intervention(s) / exposure
Experimental: Veliparib with Temozolomide - Veliparib 40 mg twice daily (BID) Days 1 through 7 plus TMZ 150 to 200 mg/m\^2 QD Days 1 through 5 in each 28-day cycle.
Placebo comparator: Placebo with Carboplatin and Paclitaxel - Placebo BID Days 1 through 7 plus carboplatin target area under the curve (mg•min/mL) (AUC) 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m\^2 administered on Day 3 of each 21-day cycle.
Experimental: Veliparib with Carboplatin and Paclitaxel - Veliparib 80 mg BID Days 1 through 7 plus carboplatin target AUC 6 administered on Day 3 of each 21-day cycle and paclitaxel 175 mg/m\^2 administered on Day 3 of each 21-day cycle.
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-Free Survival (PFS)
Query!
Assessment method [1]
0
0
PFS is defined as the number of months from the date the participant was randomized to the date of radiographic progression as determined by the central imaging center, or to the date of all cause deaths within 63 days of last tumor assessment if disease progression was not reached.
Query!
Timepoint [1]
0
0
Radiographic evaluation every 9 weeks, clinical evaluation every cycle (data cutoff date: 04 March 2016); maximum duration of follow up for PFS was 34 months.
Query!
Secondary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
Time to death for a given participant was defined as the number of months from the day the participant is randomized to the date of the participant's death. All events of death were included, regardless of whether the event occurs while the participant was still taking study drug, or after the participant discontinued study drug. If a participant had not died, then the data will be censored at the date when the participant was last known to be alive.
Query!
Timepoint [1]
0
0
From Cycle 1 Day 1 until participant's death or 3 years post discontinuation (data cutoff date: 04 March 2016); maximum duration of follow up for OS was 72 months.
Query!
Secondary outcome [2]
0
0
Clinical Benefit Rate (CBR) at Week 18
Query!
Assessment method [2]
0
0
CBR: percentage of participants who were progression-free at 18 weeks, defined as complete response (CR), partial response (PR), stable disease (SD) or non-CR/non-disease progression (PD) per Response Evaluation Criteria in Solid Tumors \[RECIST\] 1.1.
CR: The disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 0 mm. PR: \>= 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters (SOD). PD: \>= 20% increase in the SOD of target lesions, taking as reference the smallest SOD recorded since the treatment started (baseline or after) or the appearance of \>=1 new lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD since the treatment started (baseline or after).
Query!
Timepoint [2]
0
0
Week 18
Query!
Secondary outcome [3]
0
0
Objective Response Rate (ORR)
Query!
Assessment method [3]
0
0
The objective response rate, defined as percentage of participants with a confirmed CR or PR based on RECIST 1.1 criteria. CR: The disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 0 mm. PR: \>= 30% decrease in the sum of diameters of target lesions, taking as reference the baseline SODs.
Query!
Timepoint [3]
0
0
Radiographic evaluation every 9 weeks, clinical evaluation every cycle (data cutoff date: 04 March 2016); maximum duration of follow up for ORR was 34 months.
Query!
Secondary outcome [4]
0
0
Change From Baseline at Week 18 in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Chemotherapy-Induced Peripheral Neuropathy Module (EORTC QLQ-CIPN20) Sensory Subscale Score
Query!
Assessment method [4]
0
0
EORTC QLQ-CIPN20 sensory subscale score was calculated following the standard scoring algorithm, transformed to a 0 (low quality of life) to 100 (best quality of life) scale. A positive change from baseline indicates improvement.
Query!
Timepoint [4]
0
0
Baseline, Week 18
Query!
Eligibility
Key inclusion criteria
* Histologically or cytologically confirmed breast cancer that is either locally recurrent or metastatic.
* Locally recurrent disease must not be amenable to surgical resection or radiation with curative intent.
* Must have a documented deleterious Breast Cancer Gene BRCA1 or BRCA2 germline mutation.
* If Human Epidermal Growth Factor Receptor (HER2) positive, subjects must have received and progressed on at least one prior standard HER2 directed therapy or the subject must be ineligible to receive anti-HER2 therapy.
* Measurable or non-measurable (but radiologically evaluable) disease by RECIST (Response Evaluation Criteria in Solid Tumors) criteria 1.1.
* Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-2.
* Subject must have adequate bone marrow, renal and hepatic function.
* Subject must not be pregnant or plan to conceive a child.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Received anticancer agent(s) or an investigational agent within 21 days prior to C1D1, or radiotherapy within 28 days prior Cycle 1 Day 1.
* More than 2 prior lines of cytotoxic chemotherapy.
* Prior treatment of breast cancer with temozolomide, a platinum agent, or a Poly (ADP ribose) Polymerase (PARP) inhibitor.
* Prior taxane therapy for metastatic breast cancer.
* A history of or evidence of brain metastases or leptomeningeal disease.
* A history of uncontrolled seizure disorder.
* Pre-existing neuropathy from any cause in excess of Grade 1.
* Known history of allergic reaction to cremophor/paclitaxel.
* Clinical significant uncontrolled conditions, active infection, myocardial infarction, stroke, or transient ischemic attack, psychiatric illness/social situations that would limit compliance.
* Pregnant or breastfeeding.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
23/01/2012
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
2/09/2020
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
294
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,TAS,VIC,WA
Query!
Recruitment hospital [1]
0
0
The Prince of Wales Hospital /ID# 63271 - Randwick
Query!
Recruitment hospital [2]
0
0
Southern Medical Day Care Ctr /ID# 63274 - Wollongong
Query!
Recruitment hospital [3]
0
0
Mater Misericordiae Limited /ID# 63276 - South Brisbane
Query!
Recruitment hospital [4]
0
0
Royal Adelaide Hospital /ID# 63280 - Adelaide
Query!
Recruitment hospital [5]
0
0
Royal Hobart Hospital /ID# 63279 - Hobart
Query!
Recruitment hospital [6]
0
0
Peter MacCallum Cancer Ctr /ID# 63272 - Melbourne
Query!
Recruitment hospital [7]
0
0
Royal Melbourne Hospital /ID# 63278 - Parkville
Query!
Recruitment hospital [8]
0
0
Mount Hospital /ID# 65262 - Perth
Query!
Recruitment postcode(s) [1]
0
0
2031 - Randwick
Query!
Recruitment postcode(s) [2]
0
0
2500 - Wollongong
Query!
Recruitment postcode(s) [3]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [4]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [5]
0
0
7000 - Hobart
Query!
Recruitment postcode(s) [6]
0
0
3000 - Melbourne
Query!
Recruitment postcode(s) [7]
0
0
3050 - Parkville
Query!
Recruitment postcode(s) [8]
0
0
6000 - Perth
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Maryland
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Massachusetts
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Michigan
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Missouri
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
New York
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
North Carolina
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Pennsylvania
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
South Carolina
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Tennessee
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Texas
Query!
Country [18]
0
0
Argentina
Query!
State/province [18]
0
0
Berazategui, Buenos Aires
Query!
Country [19]
0
0
Argentina
Query!
State/province [19]
0
0
Santa Fe
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Bruxelles-Capitale
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Hainaut
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
West-Vlaanderen
Query!
Country [23]
0
0
Belgium
Query!
State/province [23]
0
0
Edegem
Query!
Country [24]
0
0
Belgium
Query!
State/province [24]
0
0
Leuven
Query!
Country [25]
0
0
Belgium
Query!
State/province [25]
0
0
Namur
Query!
Country [26]
0
0
Brazil
Query!
State/province [26]
0
0
Rio Grande Do Sul
Query!
Country [27]
0
0
Canada
Query!
State/province [27]
0
0
Ontario
Query!
Country [28]
0
0
Canada
Query!
State/province [28]
0
0
Quebec
Query!
Country [29]
0
0
Czechia
Query!
State/province [29]
0
0
Brno
Query!
Country [30]
0
0
Czechia
Query!
State/province [30]
0
0
Olomouc
Query!
Country [31]
0
0
Czechia
Query!
State/province [31]
0
0
Prague
Query!
Country [32]
0
0
Denmark
Query!
State/province [32]
0
0
Syddanmark
Query!
Country [33]
0
0
Denmark
Query!
State/province [33]
0
0
Copenhagen
Query!
Country [34]
0
0
Finland
Query!
State/province [34]
0
0
Helsinki
Query!
Country [35]
0
0
Finland
Query!
State/province [35]
0
0
Tampere
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Haute-Garonne
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Ile-de-France
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Loire-Atlantique
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Rhone
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Bayonne
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Marseille
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Saint-cloud
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Strasbourg
Query!
Country [44]
0
0
Hungary
Query!
State/province [44]
0
0
Budapest
Query!
Country [45]
0
0
Hungary
Query!
State/province [45]
0
0
Debrecen
Query!
Country [46]
0
0
Hungary
Query!
State/province [46]
0
0
Szolnok
Query!
Country [47]
0
0
Israel
Query!
State/province [47]
0
0
Tel-Aviv
Query!
Country [48]
0
0
Israel
Query!
State/province [48]
0
0
Be'er Sheva
Query!
Country [49]
0
0
Israel
Query!
State/province [49]
0
0
Be'er Ya'akov
Query!
Country [50]
0
0
Israel
Query!
State/province [50]
0
0
Haifa
Query!
Country [51]
0
0
Israel
Query!
State/province [51]
0
0
Jerusalem
Query!
Country [52]
0
0
Israel
Query!
State/province [52]
0
0
Ramat Gan
Query!
Country [53]
0
0
Israel
Query!
State/province [53]
0
0
Rehovot
Query!
Country [54]
0
0
Netherlands
Query!
State/province [54]
0
0
Rotterdam
Query!
Country [55]
0
0
Norway
Query!
State/province [55]
0
0
Hordaland
Query!
Country [56]
0
0
Poland
Query!
State/province [56]
0
0
Podkarpackie
Query!
Country [57]
0
0
Poland
Query!
State/province [57]
0
0
Bydgoszcz
Query!
Country [58]
0
0
Poland
Query!
State/province [58]
0
0
Olsztyn
Query!
Country [59]
0
0
Poland
Query!
State/province [59]
0
0
Poznan
Query!
Country [60]
0
0
Romania
Query!
State/province [60]
0
0
Bucharest
Query!
Country [61]
0
0
Romania
Query!
State/province [61]
0
0
Cluj
Query!
Country [62]
0
0
Romania
Query!
State/province [62]
0
0
Craiova
Query!
Country [63]
0
0
Russian Federation
Query!
State/province [63]
0
0
Moskva
Query!
Country [64]
0
0
Russian Federation
Query!
State/province [64]
0
0
Chelyabinsk
Query!
Country [65]
0
0
Russian Federation
Query!
State/province [65]
0
0
Murmansk
Query!
Country [66]
0
0
Russian Federation
Query!
State/province [66]
0
0
Novosibirsk
Query!
Country [67]
0
0
Russian Federation
Query!
State/province [67]
0
0
Pyatigorsk
Query!
Country [68]
0
0
Russian Federation
Query!
State/province [68]
0
0
St. Petersburg
Query!
Country [69]
0
0
Russian Federation
Query!
State/province [69]
0
0
Volzhsky
Query!
Country [70]
0
0
Spain
Query!
State/province [70]
0
0
Barcelona
Query!
Country [71]
0
0
Spain
Query!
State/province [71]
0
0
Madrid
Query!
Country [72]
0
0
Spain
Query!
State/province [72]
0
0
Malaga
Query!
Country [73]
0
0
Spain
Query!
State/province [73]
0
0
Valencia
Query!
Country [74]
0
0
Sweden
Query!
State/province [74]
0
0
Skane Lan
Query!
Country [75]
0
0
Sweden
Query!
State/province [75]
0
0
Goteborg
Query!
Country [76]
0
0
Sweden
Query!
State/province [76]
0
0
Solna
Query!
Country [77]
0
0
Ukraine
Query!
State/province [77]
0
0
Cherkasy
Query!
Country [78]
0
0
Ukraine
Query!
State/province [78]
0
0
Dnipro
Query!
Country [79]
0
0
Ukraine
Query!
State/province [79]
0
0
Kharkiv
Query!
Country [80]
0
0
Ukraine
Query!
State/province [80]
0
0
Lviv
Query!
Country [81]
0
0
Ukraine
Query!
State/province [81]
0
0
Odesa
Query!
Country [82]
0
0
Ukraine
Query!
State/province [82]
0
0
Poltava
Query!
Country [83]
0
0
Ukraine
Query!
State/province [83]
0
0
Sumy
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
AbbVie
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective of the study is to assess the progression-free survival (PFS) of oral veliparib in combination with TMZ or in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in subjects with BRCA1 or BRCA2 mutation and locally recurrent or metastatic breast cancer.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01506609
Query!
Trial related presentations / publications
Han HS, Dieras V, Robson M, Palacova M, Marcom PK, Jager A, Bondarenko I, Citrin D, Campone M, Telli ML, Domchek SM, Friedlander M, Kaufman B, Garber JE, Shparyk Y, Chmielowska E, Jakobsen EH, Kaklamani V, Gradishar W, Ratajczak CK, Nickner C, Qin Q, Qian J, Shepherd SP, Isakoff SJ, Puhalla S. Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study. Ann Oncol. 2018 Jan 1;29(1):154-161. doi: 10.1093/annonc/mdx505. Isakoff SJ, Puhalla S, Domchek SM, Friedlander M, Kaufman B, Robson M, Telli ML, Dieras V, Han HS, Garber JE, Johnson EF, Maag D, Qin Q, Giranda VL, Shepherd SP. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncol. 2017 Feb;13(4):307-320. doi: 10.2217/fon-2016-0412. Epub 2016 Oct 14.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
AbbVie Inc.
Query!
Address
0
0
AbbVie
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Clinical study report (CSR)
Query!
When will data be available (start and end dates)?
Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered.
Query!
Available to whom?
Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/09/NCT01506609/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/09/NCT01506609/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01506609